JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Viatris Inc

Gesloten

SectorGezondheidszorg

10.36 0.58

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

10.3

Max

10.49

Belangrijke statistieken

By Trading Economics

Inkomsten

3B

-4.6M

Verkoop

328M

3.6B

Dividendrendement

4.72

Winstmarge

-0.128

Werknemers

32,000

EBITDA

2.9B

578M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+10.47% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

4.72%

2.33%

Volgende Winsten

6 nov 2025

Volgende dividenddatum

12 dec 2025

Volgende Ex Dividend datum

21 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.5B

12B

Vorige openingsprijs

9.78

Vorige sluitingsprijs

10.36

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Viatris Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 okt 2025, 09:10 UTC

Populaire aandelen

Stocks to Watch Thursday: HSBC, PepsiCo, MP Materials -- WSJ

Peer Vergelijking

Prijswijziging

Viatris Inc Prognose

Koersdoel

By TipRanks

10.47% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 11.5 USD  10.47%

Hoogste 15 USD

Laagste 8 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Viatris Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

4 ratings

1

Buy

2

Hold

1

Sell

Technische score

By Trading Central

8.48 / N/ASteun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Very Strong Bullish Evidence

Lange Termijn

Strong Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Viatris Inc

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
help-icon Live chat